With the first implantation of the Berlin Heart Venous Cannula at the LMU University Hospital of Munich (Großhadern), Germany, Berlin Heart offers patients with failing Fontan circulation a chance to survive the waiting time for a donor heart. These patients are in a life-threatening condition: Their health has deteriorated so much, that they desperately need a new heart, but because of their poor end-organ function, as one reason, their chances on the waiting list are low.
The aim of this innovative therapy is to improve patients' end-organ function and haemodynamics by supporting the subpulmonary circulation. Thus, the Berlin Heart Venous Cannula builds the bridge to transplant, it builds the bridge to life, for patients with failing Fontan circulation.
Please read the press release, here: www.berlinheart.de/en/mediaroom/press-releases/press-release/berlin-heart-today-announces-ce-approval-and-first-implantation-of-an-innovative-bridging-solution-f/
The access to some or all shown products may be restricted by country-specific regulatory approvals. The use of EXCOR® VAD for adults, RVAD-support, EXCOR® venous cannulas with grafts, Excor mobile and EXCOR® Active is not FDA-approved and not available for commercial use in the US. The configuration of the EXCOR® Arterial Cannula for Graft as shown in the figure has not yet been CE marked.
